Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8306MR)

This product GTTS-WQ8306MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ8306MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8939MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ3169MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ1185MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABP 501
GTTS-WQ7554MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GC33
GTTS-WQ11454MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ9764MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JS001
GTTS-WQ15126MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ13815MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-10987
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW